Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease
New England Journal of Medicine · 2025-05 · 392 (17) · 1740-1742
DOI: 10.1056/nejme2503824 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, 2025-05. Verfasst von Daniel J Rader. Beteiligte Einrichtung: Division of Translational Medicine and Human Genetics, Penn Medicine, Philadelphia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Intervention to reduce the levels of circulating low-density lipoprotein (LDL) cholesterol and its major protein, apolipoprotein B, is one of the most effective ways to reduce the risk of cardiovascular events. However, even with aggressive lowering of the LDL cholesterol level, the risk of cardiovascular disease is not eliminated. One of the important factors contributing to such residual risk is lipoprotein(a). 1 Lipoprotein(a), which was first described in 1963, is a circulating lipoprotein similar to LDL but with a unique protein called apolipoprotein(a), which is bound to apolipoprotein B. Numerous epidemiologic studies have shown a significant association between lipoprotein(a) levels and . . .
Autor:innen und Institutionen
- Division of Translational Medicine and Human Genetics, Penn Medicine, Philadelphia.
Zitieren
APA
Rader, D. J. (2025). Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease. New England Journal of Medicine, 392(17), 1740-1742. https://doi.org/10.1056/nejme2503824
Vancouver
Rader DJ. Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease. New England Journal of Medicine. 2025;392(17):1740-1742. doi:10.1056/nejme2503824
BibTeX
@article{Rader2025,
author = {Rader, Daniel J},
title = {Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {17},
pages = {1740--1742},
doi = {10.1056/nejme2503824}
}
EUVIMED